SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
NPSP NPS Pharmaceutical
An SI Board Since August 1996
Posts SubjectMarks Bans Symbol
363 40 0 NPSP
Emcee:  Jim Langdon Type:  Unmoderated
Introduction Market Data Compact
Anyone follow this small biotech company. Its lead drug is Norcalcin for the treatment of HPT. Norcalcin is starting the second phase trials and mimicks the action of calcium by activating the calcium receptor. Recently Amgen has signed a 43.5 million dollar deal to develop and market the drug. Recently touted by George Southerland in his newsletter. Any comments apprriciated!
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
363Thanks, but we were out at $37, and it didn't quite hit my buy target last ytuck-1/11/2015
362Congrats to your mom! ;-) (Shire buys NPSP for $46/share)scaram(o)uche-1/11/2015
361So just as I was getting the weakness on a general market pullback, the Feds movtuck-10/16/2014
360nice move today. congrats on dogging this all along.mopgcw-9/10/2014
359NPSP beats by 5 cents. Natpara PDUFA date 10/24, but with an AC beforehand. I tuck-2/19/2014
358Natpara gets EU orphan designation. Not sure if a timeframe has been supplied ftuck-1/7/2014
357NPS begins pediatric SBS trial for Gattex. Assuming good results, sNDA in 2015tuck-1/7/2014
356BLA for Natpara submitted. Good to see, as that is in line with the latest guidtuck-10/25/2013
355Natpara data looks pretty solid, and filing for BLA this quarter (though I thinktuck-10/7/2013
354From dav1234 of Ihub (thanks!), a thumbnail valuation from BofA: >>BofA ituck-10/3/2013
353Ronacaleret: Not much has been said about this calcilytic program with GSK, so tuck-10/2/2013
352Company is presenting extension study data, and submitting sNDA for expanded labtuck-10/2/2013
351>>NPS Pharmaceuticals price target raised to $45 from $30 at Janney Capitatuck-9/25/2013
350So good to see you and your mom catch a flyer! Hope you get a few more. Rickscaram(o)uche-8/13/2013
349Somewhat giddy SA article suggesting Gattex could achieve >$2 billion in saletuck-8/13/2013
348>>NPS regains right to drugs from Takeda for $50 mln in NPS shares tuck-3/19/2013
347Gattex approved, no CC until 1/2/2013, though. Wacky day, approval expected, sotuck-12/21/2012
346AC panel unanimously backs Gattex, stock halted. Nice one Cramer. >>NPS tuck-10/17/2012
345More Natpara data: >>NPS Pharmaceuticals, Inc. ( NPSP), a biopharmaceutictuck-10/15/2012
344AC meeting next Tuesday on Gattex. Briefing docs here: http:/// Cheers, Tucktuck-10/12/2012
343EU approved Revestive a month ago: >>OSAKA, Japan & BEDMINSTER, N.J.-tuck-10/3/2012
342NPS sells post-2018 Sensipar royalties back to Amgen. >>NPS Pharmaceuticatuck-7/2/2012
341Positive CHMP opinion for teduglutide, which now has the trade name Revestive intuck-6/22/2012
340Sounds like typical SA optimism, especially wrt a buyout. Nevertheless, holdingtuck-1/23/2012
339http://seekingalpha.com/article/321380-2-high-risk-high-reward-biotechs-that-cousteve kammerer-1/23/2012
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News